Study supports Prosterol saw palmetto extract for prostate health

- Last updated on GMT

Image © iStockPhoto / cturtletrax
Image © iStockPhoto / cturtletrax

Related tags: Benign prostatic hyperplasia

A CO2 supercritical saw palmetto extract may inhibit an enzyme linked to prostate enlargement, says a new study from Euromed in Spain.

Results of the cell study, published in Research and Reports in Urology,​indicated that Euromed’s Prosterol saw palmetto extract could inhibit 5alpha-reductase, an enzyme that is the target of pharmaceuticals such as finasteride to treat enlarged prostate or benign prostate hyperplasia (BPH).

The data indicated that the Prosterol ingredient was as effective as both a saw palmetto extract made with the solvent hexane and finasteride.

“It can be confirmed from the results of this study that the [saw palmetto supercritical CO2 extract] Prosterol has bioactivity that promotes prostate health at a level that is superior to that of many other phytotherapeutic extracts,”​ wrote the researchers.

“The bioactivity of Prosterol corresponds favorably to that reported for the hexane extract used in a large number of positive BPH clinical trials, as well as to finasteride, the established standard of therapy among prescription drugs. By establishing the bioactivity of [saw palmetto supercritical CO2 extract], the present study reinforces the importance of conducting such trials prior to attempting clinical studies.

“Confirming bioactivity increases the likelihood of showing positive effects clinically, while reducing the chances of negative studies, such as those reported in the literature. Future in vitro and clinical trials involving [saw palmetto extracts] would be useful for elucidating their comparative differences as well as appropriate patient selection for their use.”

Euromed scientists performed the study and the company funded the research.

Source: Research and Reports in Urology
Volume 2016:8 Pages 41-44
“Determination of the potency of a novel saw palmetto supercritical CO2 extract (SPSE) for 5α-reductase isoform II inhibition using a cell-free in vitro test system”
Authors: P. Pais et al

Related topics: Suppliers, Botanicals, Men's Health

Related news

Related products

show more

How to Enter UK’s £690M CBD Market

How to Enter UK’s £690M CBD Market

The Association for the Cannabinoid Industry | 18-Jun-2021 | Technical / White Paper

The UK has the world’s most developed regulatory framework for legal cannabinoids, such as CBD and CBG. With a 2021 market estimated to be worth £690 million...

Your bioavailable and soluble anti-aging curcumin

Your bioavailable and soluble anti-aging curcumin

Lipofoods, a Lubrizol Company | 11-Jun-2021 | Technical / White Paper

Curcumin´s antioxidant and anti-inflammatory potential is limited by its poor solubility and its low bioavailability. In this respect, Lubrizol microencapsulated...

Robertet, hemp extracts and CBD solutions

Robertet, hemp extracts and CBD solutions

Robertet Health & Beauty | 27-May-2021 | Product Brochure

Robertet was the first flavor & fragrance company to venture into the CBD space. We have over 3 years of expertise working with this unique ingredient...

Related suppliers

Follow us

Products

View more

Webinars